BriaCell (BCTX) Therapeutics announced that it intends to offer to sell common shares and warrants in an underwritten public offering. All of the common shares and warrants are to be sold by the company. The company intends to use the net proceeds from the offering primarily for working capital requirements, general corporate purposes, and the advancement of business objectives. ThinkEquity is acting as the sole book-running manager for the offering.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Shows Promising Survival Data in Cancer Trial
- BriaCell presents OS data in MBC patients treated with Bria-IMT/CPI regimen
- BriaCell’s Phase 3 Study Progresses in Cancer Fight
- BriaCell says DSMB recommends continuation of Phase 3 study in MBC
- BriaCell Highlights Promising Breast Cancer Trial Results